137 related articles for article (PubMed ID: 37624421)
1. FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
Singh S; Bradford D; Li X; Mishra-Kalyani PS; Shen YL; Wang L; Zhao H; Xiong Y; Liu J; Charlab R; Kraft J; Khasar S; Miller CP; Rivera DR; Kluetz PG; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2024 Jan; 30(1):23-28. PubMed ID: 37624421
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Canaud G; Lopez Gutierrez JC; Irvine AD; Vabres P; Hansford JR; Ankrah N; Branle F; Papadimitriou A; Ridolfi A; O'Connell P; Turner S; Adams DM
Genet Med; 2023 Dec; 25(12):100969. PubMed ID: 37634128
[TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Narayan P; Prowell TM; Gao JJ; Fernandes LL; Li E; Jiang X; Qiu J; Fan J; Song P; Yu J; Zhang X; King-Kallimanis BL; Chen W; Ricks TK; Gong Y; Wang X; Windsor K; Rhieu SY; Geiser G; Banerjee A; Chen X; Reyes Turcu F; Chatterjee DK; Pathak A; Seidman J; Ghosh S; Philip R; Goldberg KB; Kluetz PG; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
Clin Cancer Res; 2021 Apr; 27(7):1842-1849. PubMed ID: 33168657
[TBL] [Abstract][Full Text] [Related]
4. Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.
Wenger TL; Ganti S; Bull C; Lutsky E; Bennett JT; Zenner K; Jensen DM; Dmyterko V; Mercan E; Shivaram GM; Friedman SD; Bindschadler M; Drusin M; Perkins JN; Kong A; Bly RA; Dahl JP; Bonilla-Velez J; Perkins JA
Genet Med; 2022 Nov; 24(11):2318-2328. PubMed ID: 36066547
[TBL] [Abstract][Full Text] [Related]
5. Alpelisib: A Novel Agent for PIK3CA-Related Overgrowth Spectrum.
Nadjkovic K; Lonabaugh K
J Pediatr Pharmacol Ther; 2023; 28(7):590-594. PubMed ID: 38025143
[TBL] [Abstract][Full Text] [Related]
6. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.
Morin G; Degrugillier-Chopinet C; Vincent M; Fraissenon A; Aubert H; Chapelle C; Hoguin C; Dubos F; Catteau B; Petit F; Mezel A; Domanski O; Herbreteau G; Alesandrini M; Boddaert N; Boutry N; Broissand C; Han TK; Branle F; Sarnacki S; Blanc T; Guibaud L; Canaud G
J Exp Med; 2022 Mar; 219(3):. PubMed ID: 35080595
[TBL] [Abstract][Full Text] [Related]
7. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
8. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
[TBL] [Abstract][Full Text] [Related]
9. Alpelisib (Vijoice) for PIK3CA-related overgrowth spectrum.
Med Lett Drugs Ther; 2022 Nov; 64(1663):e186-e187. PubMed ID: 36384765
[No Abstract] [Full Text] [Related]
10. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
13. Response to Alpelisib in Clinically Distinct Pediatric Patients With PIK3CA -related Disorders.
Kolitz E; Fernandes NJ; Agim NG; Ludwigl K
J Pediatr Hematol Oncol; 2022 Nov; 44(8):482-485. PubMed ID: 35129141
[TBL] [Abstract][Full Text] [Related]
14.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
15. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
16. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Mayer IA; Prat A; Egle D; Blau S; Fidalgo JAP; Gnant M; Fasching PA; Colleoni M; Wolff AC; Winer EP; Singer CF; Hurvitz S; Estévez LG; van Dam PA; Kümmel S; Mundhenke C; Holmes F; Babbar N; Charbonnier L; Diaz-Padilla I; Vogl FD; Sellami D; Arteaga CL
Clin Cancer Res; 2019 May; 25(10):2975-2987. PubMed ID: 30723140
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.
Forde K; Resta N; Ranieri C; Rea D; Kubassova O; Hinton M; Andrews KA; Semple R; Irvine AD; Dvorakova V
Orphanet J Rare Dis; 2021 Feb; 16(1):109. PubMed ID: 33639990
[TBL] [Abstract][Full Text] [Related]
19. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genetic analyses of patients with lateralized overgrowth.
Kim YM; Lee Y; Choi Y; Choi IH; Heo SH; Choi JM; Do HS; Jang JH; Yum MS; Yoo HW; Lee BH
BMC Med Genomics; 2022 Sep; 15(1):206. PubMed ID: 36175890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
